Actively Recruiting
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
Led by The First Affiliated Hospital of Xiamen University · Updated on 2026-03-31
100
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the potential usefulness of 68Ga-NK224 positron emission tomography/computed tomography (PET/CT) for the evaluation of PD-L1 expression in primary and/or metastatic tumors, compared with histopathological results.
CONDITIONS
Official Title
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Diagnosed with newly diagnosed or previously treated malignant tumors confirmed by MRI, CT, tumor markers, or pathology report
- Scheduled to undergo 68Ga-NK224 PET/CT scans
- Able to provide informed consent and assent according to Clinical Research Ethics Committee guidelines
You will not qualify if you...
- Patients with non-malignant lesions
- Pregnant patients
- Patients unable or unwilling to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361000
Actively Recruiting
Research Team
L
Liang Zhao
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here